However, tumor recurrence was observed after the cessation of treatment (Fig. 8d), suggesting that a rational combination of p53 targeting with other therapies (such as chemotherapy or immunotherapy) or increased dosage and treatment cycles may enhance the durability of the response. Here, TP53 is linked to neoplasm.